Eli Lilly and Company · 1 week ago
Advisor – In Vivo Pharmacologist – Cardiometabolic Research
Indianapolis, IN
Full-time
Onsite
Entry, Mid Level
$126K/yr - $205K/yrEli Lilly and Company is a global healthcare leader headquartered in Indianapolis, Indiana, focused on discovering and delivering life-changing medicines. They are seeking a PhD-level in vivo physiologist to advance their Cardiometabolic Research Therapeutic Area by designing and implementing in vivo studies to validate novel therapeutic targets for obesity and related metabolic disorders.
BiotechnologyHealth CareMedicalPharmaceutical
Responsibilities
Design and implement in vivo studies to interrogate mechanisms and pathways relevant to novel obesity and metabolic disease therapeutics, establishing and optimizing preclinical models as needed
Conduct hands-on laboratory work applying expertise in adipose tissue physiology to develop and implement in vivo and ex vivo systems that generate critical data supporting target validation and program advancement
Work independently and collaboratively within a cross-functional team environment, effectively communicating scientific findings and experimental plans to diverse partners
Provide technical mentorship and day-to-day guidance to 1-2 research associates, contributing to their scientific development
Maintain rigorous experimental documentation, perform independent data analysis, and communicate results through written reports and oral presentations in compliance with Lilly research standards
Qualification
Required
Ph.D. in physiology, molecular biology, pharmacology, or a closely related field
Demonstrated experience designing, executing, and analyzing in vivo metabolic studies in rodent models of obesity and/or metabolic disease
Preferred
Postdoctoral training with a track record of peer-reviewed publications in high-impact journal demonstrating contributions to adipose biology or metabolic disease
Experience with metabolic phenotyping techniques including body composition analysis, indirect calorimetry and glucose/insulin tolerance testing
Proficiency in molecular biology techniques relevant to metabolic research (RT-qPCR, Western blot, ELISA, immunohistochemistry, etc)
Hands-on experience with primary adipocyte isolation, differentiation, and functional assays, or other ex vivo adipose tissue models
Familiarity with genetic medicine approaches (siRNA, ASO) and their application in metabolic disease models
Strong analytical skills with experience in statistical analysis software
Proven ability to manage multiple projects simultaneously, prioritize effectively, and demonstrate scientific initiative
Excellent written and oral communication skills with experience presenting at scientific conferences or symposia
Benefits
Company bonus (depending, in part, on company and individual performance)
Eligibility to participate in a company-sponsored 401(k)
Pension
Vacation benefits
Eligibility for medical, dental, vision and prescription drug benefits
Flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts)
Life insurance and death benefits
Certain time off and leave of absence benefits
Well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities)
Company
Eli Lilly and Company
We're a medicine company turning science into healing to make life better for people around the world.
Founded in 1876
10001+ employees
H1B Sponsorship
Eli Lilly and Company has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (514)
2024 (236)
2023 (167)
2022 (133)
2021 (57)
2020 (52)
Funding
Current Stage
Public CompanyTotal Funding
$6.5M2024-02-12Post Ipo Debt· $6.5M
1978-01-13IPO
Leadership Team
David Ricks
Chair, CEO
Lucas Montarce
Executive Vice President and Chief Financial Officer
Recent News
2026-01-21
Company data provided by crunchbase